B-cell acute lymphoblastic leukemia (Cancer)
Information
- Disease name
- B-cell acute lymphoblastic leukemia
- Disease ID
- DOID:0080638
- Description
- "An acute lymphocytic leukemia characterized by too many B-cell lymphoblasts (immature white blood cells) in the bone marrow and blood." [url:https\://www.cancer.gov/publications/dictionaries/cancer-terms/def/b-cell-acute-lymphoblastic-leukemia]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03467256 | Active, not recruiting | Phase 1/Phase 2 | CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL | May 14, 2018 | October 15, 2025 |
| NCT03962465 | Active, not recruiting | Phase 1 | Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL | July 22, 2022 | July 2026 |
| NCT02435849 | Completed | Phase 2 | Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients | April 8, 2015 | November 17, 2022 |
| NCT02730312 | Completed | Phase 1 | PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies | August 2016 | September 2021 |
| NCT03289455 | Completed | Phase 1/Phase 2 | CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL) | June 26, 2017 | May 18, 2020 |
| NCT02746952 | Completed | Phase 1 | Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia | August 1, 2016 | July 28, 2020 |
| NCT03825718 | Completed | Early Phase 1 | A Study of GC007F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL | January 17, 2019 | December 1, 2020 |
| NCT05130489 | Completed | CAR T Cell Therapy Related Cardiovascular Outcomes | January 18, 2021 | May 1, 2023 | |
| NCT02228096 | Completed | Phase 2 | Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients | August 14, 2014 | May 24, 2019 |
| NCT00289562 | Completed | Phase 1/Phase 2 | Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia | September 2004 | December 2007 |
| NCT01207388 | Completed | Phase 2 | Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL) | November 2010 | January 7, 2019 |
| NCT06009107 | Not yet recruiting | Phase 1/Phase 2 | A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL) | August 31, 2024 | December 30, 2026 |
| NCT04595162 | Not yet recruiting | Phase 1 | A Study of GC019F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL | March 15, 2021 | December 15, 2035 |
| NCT06393985 | Not yet recruiting | Phase 2 | Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL | April 25, 2024 | April 25, 2027 |
| NCT06389305 | Not yet recruiting | N/A | CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction | June 1, 2024 | May 30, 2026 |
| NCT06326008 | Not yet recruiting | Phase 1 | Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial | June 15, 2024 | December 30, 2026 |
| NCT06208735 | Not yet recruiting | Phase 1 | CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies | July 1, 2024 | August 1, 2027 |
| NCT06450067 | Not yet recruiting | Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia | June 5, 2024 | June 5, 2029 | |
| NCT06395103 | Not yet recruiting | Phase 1/Phase 2 | Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) | June 4, 2024 | March 31, 2029 |
| NCT06080191 | Recruiting | Phase 1 | Allogeneic Second-generation CD19-CAR T Cells for Pediatric Relapsed/Refractory B-ALL | April 28, 2024 | June 1, 2041 |
| NCT03509961 | Recruiting | Phase 2 | The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL | August 29, 2018 | July 1, 2026 |
| NCT03595917 | Recruiting | Phase 1 | ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML | July 24, 2018 | November 1, 2026 |
| NCT03666000 | Recruiting | Phase 1/Phase 2 | Dose-escalation, Dose-expansion Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL | March 11, 2019 | June 2024 |
| NCT03876769 | Recruiting | Phase 2 | Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients | June 24, 2019 | October 19, 2027 |
| NCT05020678 | Recruiting | Phase 1 | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers | August 20, 2021 | December 2038 |
| NCT05082519 | Recruiting | Phase 2 | Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL | March 12, 2022 | October 15, 2031 |
| NCT05210907 | Recruiting | Phase 1 | Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic Leukemia | February 15, 2022 | August 31, 2026 |
| NCT05262673 | Recruiting | Phase 1 | NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL | March 1, 2022 | December 31, 2025 |
| NCT05333302 | Recruiting | Phase 1 | Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma | October 26, 2020 | June 2023 |
| NCT05379647 | Recruiting | Phase 1 | Natural Killer (NK) Cell Therapy for B-Cell Malignancies | November 4, 2021 | December 2024 |
| NCT05460533 | Recruiting | Phase 2 | A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL) | July 12, 2022 | July 2026 |
| NCT05470777 | Recruiting | Phase 1/Phase 2 | CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL | January 19, 2020 | December 31, 2024 |
| NCT05559450 | Recruiting | Phase 2 | Blinatumomab as a Bridge to Allo-HSCT in HR BCP-ALL | February 1, 2022 | January 2026 |
| NCT05639179 | Recruiting | Phase 1/Phase 2 | Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL | December 5, 2022 | December 31, 2025 |
| NCT05648019 | Recruiting | Phase 2 | CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol | March 15, 2022 | December 2026 |
| NCT05651191 | Recruiting | Early Phase 1 | To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL | October 21, 2022 | September 30, 2025 |
| NCT05667506 | Recruiting | Phase 1/Phase 2 | A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric) | February 7, 2023 | December 30, 2025 |
| NCT05674175 | Recruiting | Phase 1/Phase 2 | Co-administration of CART22-65s and huCART19 for B-ALL | January 25, 2023 | January 15, 2029 |
| NCT05747157 | Recruiting | Early Phase 1 | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10- 19) in the Treatment of r/r B-ALL Clinical Research | February 15, 2023 | May 15, 2025 |
| NCT06027957 | Recruiting | Phase 1 | CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia | August 2, 2023 | July 31, 2025 |
| NCT06034275 | Recruiting | Phase 1 | Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies | September 13, 2023 | December 31, 2025 |
| NCT06056752 | Recruiting | Phase 1 | QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia | September 27, 2023 | July 3, 2026 |
| NCT06081478 | Recruiting | Phase 2 | CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia | January 18, 2022 | December 31, 2026 |
| NCT06220097 | Recruiting | Phase 2 | Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies | February 1, 2024 | December 30, 2025 |
| NCT06343090 | Recruiting | N/A | Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients | April 12, 2024 | September 30, 2043 |
| NCT04094311 | Recruiting | Phase 3 | Study of Out of Specification for Tisagenlecleucel | November 21, 2019 | April 18, 2025 |
| NCT04150497 | Recruiting | Phase 1 | Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01) | October 14, 2019 | January 31, 2026 |
| NCT04534634 | Recruiting | Phase 2 | Study of IFN-α Combined With CAR-T Cell Therapy in Relapsed and Refractory Acute Lymphoblastic Leukemia（R/R-ALL） | April 1, 2019 | July 31, 2025 |
| NCT04544592 | Recruiting | Phase 1/Phase 2 | UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL | February 24, 2021 | July 2026 |
| NCT04556084 | Recruiting | Phase 2 | Blinatumomab Bridging Therapy | January 1, 2021 | October 2024 |
| NCT04746209 | Recruiting | Phase 2 | Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT | February 1, 2021 | December 31, 2029 |
| NCT05016947 | Recruiting | Phase 1 | Venetoclax Plus Inotuzumab for B-ALL | September 24, 2021 | June 23, 2026 |
| NCT01974479 | Suspended | Phase 1 | Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia | September 2013 | February 2020 |
| NCT04844086 | Terminated | Phase 1 | RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies | March 2, 2021 | May 12, 2022 |
| NCT04191941 | Unknown status | Early Phase 1 | Treatment of Hematological Malignancy With Novel CAR-T Cells. | September 1, 2019 | December 31, 2021 |
| NCT03825731 | Unknown status | Early Phase 1 | A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL | January 17, 2019 | September 16, 2019 |
| NCT03000335 | Unknown status | Evaluation of ProALL miRs in Blood Specimen for Prediction of ALL Relapse Risk | December 2016 | December 2021 | |
| NCT04264039 | Unknown status | Early Phase 1 | Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies | April 1, 2020 | April 1, 2022 |
| NCT04289220 | Unknown status | Phase 1 | Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia | March 15, 2020 | September 15, 2023 |
| NCT04129099 | Unknown status | Early Phase 1 | A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL | October 22, 2019 | June 2022 |
| NCT03574168 | Unknown status | Phase 1 | CD19-CAR-T Cells in Patients With R/R B-ALL | July 20, 2018 | December 31, 2019 |
| NCT02924753 | Unknown status | Phase 1 | The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL). | July 18, 2016 | December 2019 |
| NCT03671460 | Unknown status | Phase 1 | CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL. | September 7, 2018 | January 1, 2021 |
| NCT03854994 | Unknown status | Phase 1 | CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia | August 1, 2018 | August 1, 2022 |
| NCT03281551 | Unknown status | Phase 1 | Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma | October 1, 2017 | November 1, 2020 |
| NCT04747093 | Unknown status | Phase 1/Phase 2 | Induced-T Cell Like NK Cells for B Cell Malignancies | January 29, 2021 | March 31, 2022 |
| NCT03638206 | Unknown status | Phase 1/Phase 2 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | March 1, 2018 | March 1, 2023 |
| NCT02167360 | Withdrawn | Phase 2 | Study of Efficacy and Safety of CTL019 in Adult ALL Patients | June 2016 | |
| NCT04156659 | Withdrawn | Phase 2 | Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or Refractory B-cell ALL | November 30, 2021 | November 30, 2027 |
| NCT04448834 | Withdrawn | Phase 2 | Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphi CD19+ ALL | January 2022 | June 1, 2023 |
| NCT03982992 | Withdrawn | Phase 2 | Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab | June 1, 2019 | November 30, 2021 |
| NCT05571540 | Withdrawn | Phase 1/Phase 2 | Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL | October 1, 2022 | October 31, 2024 |
| NCT05613348 | Withdrawn | Phase 1/Phase 2 | CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma | December 1, 2022 | December 1, 2028 |
- Disase is a (Disease Ontology)
- DOID:9952
- Cross Reference ID (Disease Ontology)
- NCI:C8644
- Exact Synonym (Disease Ontology)
- B acute lymphoblastic leukemia
- Exact Synonym (Disease Ontology)
- B-cell acute lymphocytic leukemia